Exposome Epidemiology for Suspect Environmental Chemical Exposures during Pregnancy Linked to Subsequent Breast Cancer Diagnosis

Young-Mi Go¹, Jaclyn Weinberg¹, Sami Teeny¹, Piera Cirillo², Nickilou Krigbaum², Grant Singer¹, ViLinh Ly¹, Barbara Cohn^{2†} and Dean P. Jones^{1†}

¹Clinical Biomarkers Laboratory, Division of Pulmonary, Allergy, Critical Care, and Sleep

Medicine, Department of Medicine, Emory University, Atlanta, GA 30322

² The Center for Research on Women and Children's Health, Child Health and Development

Studies, Public Health Institute, Berkeley, CA 94709

Running Head: Exposome epidemiology of breast cancer

[†]Corresponding authors:

DPJ: Whitehead Biomedical Research Building, 615 Michael St, Room 205P
Atlanta, GA, 30322. Phone: 404-727-5970. Fax: 404-727-2974. E-mail: <u>dpjones@emory.edu</u>
BC: 1683 Shattuck Avenue, Suite B, Berkeley, CA 94709. E-mail: bcohn@chdstudies.org

1 Author Contributions

- Designed research YMG, PC, DPJ, BC
- Performed research YMG, NK, VL, GS
- Analyzed data YMG, JW, ST, PC, NK, GS, DPJ, BC
- Wrote the paper YMG, ST, NK, PC, DPJ, BC
- 6

7 Declaration of Competing Financial Interests

8 The authors declare they have no actual or potential competing financial interests.

ABSTRACT

9 Breast cancer is now the most common cancer globally, accounting for 12% of all new annual 10 cancer cases worldwide. Despite epidemiologic studies having established a number of risk 11 factors, knowledge of chemical exposure risks is limited to a relatively small number of chemicals. In this exposome research study, we used non-targeted, high-resolution mass 12 13 spectrometry (HRMS) of pregnancy cohort biospecimens in the Child Health and Development Studies (CHDS) to test for associations with breast cancer identified via the California Cancer 14 Registry. Second (T2) and third (T3) trimester archival samples were analyzed from 182 women 15 16 who subsequently developed breast cancer and 384 randomly selected women who did not develop breast cancer. Environmental chemicals were annotated with the Toxin and Toxin-17 Target Database (T3DB) for chemical signals that were higher in breast cancer cases and used 18 19 with an exposome epidemiology analytic framework to identify suspect chemicals and associated metabolic networks. Network and pathway enrichment analyses showed consistent linkage in 20 21 both T2 and T3 to inflammation pathways, including linoleate, arachidonic acid and 22 prostaglandins, and identified new suspect environmental chemicals associated with breast cancer, i.e., an N-substituted piperidine insecticide and a common commercial product, 2,4-23 dinitrophenol (DNP), linked to variations in amino acid and nucleotide pathways in T2 and 24 25 benzo[a]carbazole and a benzoate derivative linked to glycan and amino sugar metabolism in T3. The results identify new suspect environmental chemical risk factors for breast cancer and 26 27 provide an exposome epidemiology framework for discovery of suspect environmental chemicals and potential mechanistic associations with breast cancer. 28

29

30 Keywords: Cancer, exposome, metabolomics, pregnancy

31 Abbreviations

- BC, breast cancer; FDR, false discovery rate; HRM, high-resolution metabolomics; HRMS,
- high-resolution mass spectrometry; LC-HRMS, liquid chromatography-high resolution mass
- 34 spectrometry; MWAS, metabolome-wide association study; m/z, mass to charge; RT, retention
- time; T2, second trimester; T3, third trimester, T3DB, the toxin and toxin-targeted database.

36 1. Introduction

37 High-resolution metabolomics (HRM) uses advanced mass spectrometry and data science for non-targeted analysis of biological samples to obtain insight into an individual's metabolism 38 39 along with the individual's exposome, including chemicals derived from diet, intestinal microbiome, dietary supplements, pharmaceuticals, personal use products and environmental 40 41 exposures (Jones *et al.* 2012). The metabolome is a functional readout of the interactions of a person's genes with exposures from diet and environment (Johnson et al. 2017; Jones et al. 2016; 42 Niedzwiecki et al. 2019) and has been used extensively in combination with exposure 43 44 measurements, such as air pollution (Liang et al. 2018; Ritz et al. 2022) and targeted environmental chemicals, such as DDT, PCBs and PBB (Hu et al. 2020; Walker et al. 2019), to 45 gain understanding of functional associations with exposures. Use in a non-targeted manner for 46 discovery of new chemical associations with disease, however, are limited. A vision for 47 development of exposome epidemiology, i.e., using omics scale biomonitoring for disease 48 epidemiology, is available (Jones and Cohn 2020). The current study was undertaken to apply 49 50 exposome epidemiology concepts for discovery of potential new environmental factors contributing to breast cancer. The long-term goal for complex diseases such as breast cancer, 51 which involves multiple genetic, behavioral and environmental factors, is to integrate omics 52 53 scale biomonitoring with other factors to ultimately improve prediction and intervention strategies to decrease disease burden. 54

To perform a non-targeted exposome-wide association study of breast cancer, we used archival blood samples from the, Child Health and Development Studies (CHDS) cohort collected during pregnancy from 1959-1967. Second (T2) and third (T3) trimester archival

samples, collected from 1959-1967, of 182 women who subsequently developed breast cancer,
were compared to those from 384 women who did not develop breast cancer.

We developed an exposome epidemiology approach (Fig 1) in which we first performed 60 non-targeted statistical analysis to select HRM features that were higher in cases than in non-61 cases. In this selection, we use raw p < 0.05 as a cutoff for selection based upon the expectation 62 63 that multiple environmental factors with small effect size may contribute to breast cancer, and this more liberal selection criteria is more appropriate for a small-population discovery study 64 because it provides a better balance between Type 1 and Type 2 statistical error than more 65 66 rigorous False Discovery Rate (FDR) criteria. We selected HRM features that were higher in cases than non-cases to search for potentially causative factors by matching to a xenobiotic 67 database, Toxin and Toxin-Target Database (T3DB) (Lim et al. 2010; Wishart et al. 2015), 68 recognizing that protective factors that are decreased in association with breast cancer would 69 prioritize use of HRM features that were lower in cases and an alternative database, such as Food 70 71 Database (FoodDB) (Scalbert et al. 2011). HRM features that were increased with breast cancer 72 and annotated as environmental chemicals were then used for network analysis with the datadependent community detection tool, xMWAS (Uppal et al. 2018). Pathway enrichment 73 analysis of the most central communities was then performed with *mummichog* (Li *et al.* 2013), 74 75 and targeted mass spectrometry was used to improve understanding of the annotated chemicals associated with breast cancer outcome. The results provide evidence for new candidate 76 77 environmental breast carcinogens and information concerning possible mechanisms by which 78 these agents contribute to breast cancer.

79

The CHDS recruited women residing in the Oakland and East Bay, California area who

80 2. Materials and methods

81 *2.1 Samples and Assays*

82

83 were members of the Kaiser Foundation Health Plan and received obstetric care for pregnancies 84 between 1959 and 1966 with deliveries extending into 1967 (van den Berg et al. 1988). More 85 than 98% of all eligible women enrolled. Blood samples were collected from these mothers during pregnancy in each trimester and 86 in the early post-partum period, processed to isolate serum, and stored since then at -20° Celsius. 87 88 Second and third trimester archival samples available were analyzed for HRM and 89 environmental chemicals. The samples used for the present study include second (T2, n=182)) 90 and third (T3, n=172)) trimester archival samples of 201 women who subsequently developed 91 breast cancer, compared to second (T2, n=384) and third (T3, n=351) trimester archival samples from 413 women who did not develop breast cancer. Breast cancer cases were identified by 92 93 linkage to the California Cancer Registry for cases diagnosed through 1997. Record abstraction 94 for cancer diagnoses to the California Cancer Registry is based primarily on pathology reports, and case identification is considered to be >99% complete after a 2-year lag (Perkins et al.). 95 Cases were defined as mothers with incident invasive or noninvasive breast cancer diagnosed at 96 97 a median age at diagnosis of 54 years (interquartile range, 13 years) with available prenatal 98 serum and a standardized gross placental exam. Non-cases were an 8% sample of women not 99 known to have breast cancer randomly selected among mothers with available prenatal serum and a standardized gross placental exam (Cohn et al. 2017). Breast cancer rates for included and 100 101 excluded subsets in the CHDS cohort were highly comparable suggesting selection did not impose significant bias: 1.89 per 1,000 person-years (95% Confidence Interval ([95% CI] = 1.60, 102

103 2.23) for included vs. 1.88 per 1,000 (95% CI=1.59, 2.20) for excluded. It is possible, however, 104 that we missed some cases of breast cancer, including among women who are identified in this study as "non-cases". In this case, failure to identify cases among the non-case group would 105 106 result in underestimating differences between cases and non-cases in these analyses and would not be expected to impact findings. The CHDS founding mothers voluntarily participated in an 107 in-person interview and gave permission to access their own medical records and those of their 108 109 children to researchers. The institutional review board of the Public Health Institute approved the present study (IRB#120-002), and we complied with all federal guidelines governing the use of 110 111 human participants. Forty-six percent of cases and forty-five percent of the non-cases had available data and serum. 112

113

114 2.2 Chemicals

115 HPLC grade acetonitrile and methanol, LC-MS water and 98% formic acid were obtained from

116 Sigma-Aldrich (St. Louis, MO). A mixture of 14 stable isotopic chemicals were used as an

- internal standard (Go *et al.* 2015) included $[{}^{13}C_6]$ -D-glucose, $[{}^{15}N]$ -indole, $[2-{}^{15}N]$ -L-lysine
- 118 dihydrochloride, $[{}^{13}C_5]$ -L-glutamic acid, $[{}^{13}C_7]$ -benzoic acid, $[3,4-{}^{13}C_2]$ -cholesterol, $[{}^{15}N]$ -L-
- 119 tyrosine, [trimethyl- ${}^{13}C_3$]-caffeine, [${}^{15}N_2$]-uracil, [3,3- ${}^{13}C_2$]-cystine, [1,2- ${}^{13}C_2$]-palmitic acid,
- 120 $[^{15}N, ^{13}C_5]$ -L-methionine, $[^{15}N]$ -choline chloride and 2'-deoxyguanosine- $^{15}N_2, ^{13}C_{10}$ -5'-
- 121 monophosphate from Cambridge Isotope Laboratories, Inc (Andover, PA).

- 123 2.3 High-resolution mass spectrometry. Serum samples were analyzed with liquid
- 124 chromatography-high resolution mass spectrometry (LC-HRMS) as described previously (Jarrell
- 125 *et al.* 2021; Jarrell *et al.* 2020). Briefly, 50 μL of serum was treated 2:1 (v/v) with acetonitrile,

126 and 2.5 μ L of the stable isotope standard mixture was added. Proteins were precipitated by 127 incubation at 4° C for 30 min and removed by centrifugation for 10 min at 21000 x g at 4° C. Supernatants were placed in autosampler vials and maintained at 4° C in an autosampler until 128 129 analysis. Two pooled human reference samples including NIST SRM1950 and Qstd [pooled plasma from 2 separate lots from Equitech-Bio, Inc (Kerrville, Texas)] were included. NIST 130 131 SRM1950 was run at the beginning and end of the full sample set, and Qstd was included at the beginning and end of each batch of 20 samples. 132 Samples and reference materials were analyzed with three technical replicates using a 133 134 High-Field Q-Exactive mass spectrometer (Thermo Fisher) with C18 chromatography and electrospray ionization (ESI) in negative mode. Data collection occurred continuously 135 throughout 5 min of chromatographic separation from 85 to 1,275 mass-to-charge ratio (m/z). 136 Data extraction was performed using apLCMS and xMSanalyzer, generating mass spectral 137 features consisting of m/z, retention time (RT) and peak intensity. Feature and sample filtering 138 retained features with a median CV of 50% or less, a minimum mean Pearson correlation 139 140 coefficient of 0.7 between technical replicates of each sample, and presence in at least 30% of samples. 141

142

2.4 Selection of features associated with subsequent breast cancer. A Metabolome-Wide
Association Study (MWAS) was used to identify *m/z* features associated with breast cancer
outcome. Intensity values were log2 transformed, and LIMMA was performed using the R
package, *xmsPANDA* (https://github.com/kuppal2/xmsPANDA), with retention of features at raw *p*<0.05.

148

2.5 Annotation of Mass Spectral Features and Metabolite Identification. To select mass spectral
features of environmental interest, features positively associated with subsequent breast cancer
diagnosis were subjected to a multistage clustering algorithm and annotated with xMSannotator
(Uppal *et al.* 2017) using T3DB (Lim *et al.* 2010; Wishart 2015) at 5 ppm tolerance. For
selected chemicals, identities were confirmed when possible by accurate *m/z* match, co-elution
with authentic standards and ion dissociation mass spectrometry (MS/MS); Level 1 identification
by criteria of Schymanski et al (Schymanski *et al.* 2014)].

156

2.6 Targeted mass spectrometry analysis in identification of features. Annotated chemicals at the 157 center of the *xMWAS* network structures underwent additional investigation by ion fragmentation, 158 structure analysis, and spectral matching to publicly available spectral libraries. Plasma samples 159 160 with the highest intensities of the chemicals of interest were selected and analyzed with C18 liquid chromatography (Dionex Ultimate 3000) and MS² ion fragmentation (Thermo Scientific 161 Fusion) with negative ESI. The mass spectrometer was set to scan a minimal range of m/z's at 162 60k resolution for MS¹. Then, an inclusion list isolated the m/z of interest. MS² fragmentation 163 was acquired in HCD mode with a normalized collision energy of 30% and analyzed at 30,000 164 resolution using the dual-pressure linear ion trap. Raw MS¹ and MS² spectra were analyzed in 165 xCalibur QualBrowser (Thermo). Fragmentation patterns were analyzed with ChemDraw 166 (PerkinElmer Informatics) and compared against experimental spectra in the MassBank of North 167 America (MoNA) library. MoNA MS² spectra were selected for negative ESI and similar 168 collision energy. When MoNA spectra were not available, experimental spectra were searched 169 170 against the NIST Tandem Mass Spectral Library, which provides a spectral match percentage but 171 no information on collision energy or ionization polarity. To align with the goal of high-

172	throughput analyses, chromatographic gradients and fragmentation settings were maintained to
173	be consistent with the original analysis and not extensively optimized for each chemical. Under
174	these conditions, the complexity of the plasma sample matrix and the low abundance of
175	environmental chemicals does not allow for the isolation of one precursor and its fragments.
176	Therefore, in some spectra, the precursor mass is easily visible within 10 ppm error, but the
177	fragments are not clearly visible due to interference from other ions. Spectral peaks
178	corresponding to fragments were identified by their theoretical structures in "ChemDraw" with
179	unit resolution in the dual-pressure linear ion trap detector.
180	
181	2.7 Network and Pathway Analyses. Annotated environmental chemicals were tested for
182	associations with m/z features using xMWAS based on partial least-squares regression (Uppal et
183	<i>al.</i> 2018). Thresholds for inclusion in the networks were $ \mathbf{r} > 0.30$ and $p < 0.05$. Pairwise results
184	from MWAS of the metabolites used for generation of network structures were used for pathway
185	enrichment analysis using mummichog (v3) (Li et al. 2013). Enriched pathways were filtered for
186	those that included at least 3 significantly associated metabolites at $p < 0.05$.
187	

189 **3. RESULTS**

190

- 191 *3.1 Study population demographics*
- 192 T2 and T3 samples were available from 201 individuals who subsequently developed breast
- 193 cancer. These individuals had a median age of 31 y at time of blood collection, and the
- individuals without breast cancer had a median age of 36 (p<0.0001). Serum collection occurred
- between 1960 and 1964, with T2 blood collection occurring at a median gestational age of 161
- and 160 days in cases and non-cases, respectively. For T3, blood collections were at a median
- 197 gestational age of 249 and 250 days, respectively. Characteristics of cases and non-cases are
- 198 provided in **Table 1**.
- 199
- 200 *3.2 Metabolic feature profiling on T2 and T3 serum*

To select m/z features which were positively associated with subsequent breast cancer diagnosis, 201 202 we retained 9042 m/z features present in at least 80% of samples for statistical analyses and 203 selection of features for annotation. For T2 and T3 measurements, no features had FDR<0.05 and therefore none are likely to be useful biomarkers for breast cancer risk. Any of the m/z204 205 features selected with raw p<0.05 could contribute to breast cancer risk, and 521 features had 206 p<0.05 for T2, and 557 features had p<0.05 for T3. Of these m/z features, 188 were higher in breast cancer than non-cases in T2 samples while 151 were higher in breast cancer than non-207 cases in T3 samples (**Table 2**). These positively associated m/z features were selected to search 208 for possible matches to environmental chemicals. 209

210

211 *3.3 Environmental chemical annotation of suspect chemicals in breast cancer group*

212 Most of the selected m/z features are likely to represent endogenous metabolites, but 213 environmental chemicals contributing to subsequent breast cancer could also be present. To 214 search for suspect environmental chemicals associated with subsequent breast cancer diagnosis, 215 we used xMSannotator, a network-based computational tool, with the Toxin and Toxin-Target 216 Database, T3DB (Wishart 2015; Wishart et al. 2007), to further characterize the mass spectral 217 features which were higher in their intensities in women who went on to develop breast cancer. 218 xMSannotator uses a multistage clustering algorithm in which intensity profiles, retention time 219 characteristics, mass defect, and isotope/adduct patterns are used to assign confidence levels to 220 annotation results relative to publicly available databases, such as T3DB. The annotated 221 environmental chemicals for T2 and T3 are shown in **Table 3** and **Table 4**, respectively. More environmental chemicals were annotated in T2 than T3 serum, yielding 17 and 7, respectively, 222 223 and these included matches to chemicals widely used for anti-inflammatory, anticonvulsant and antipsychotic drugs, quaternary ammonium salt, pesticides, herbicides, fungicides, plasticizers, 224 225 preservatives, cleaning materials, and flavorings. Importantly, at this level of investigation, these 226 annotations are only suspect chemicals and require further investigation and verification (see below). The magnitude of difference was between 10% and 30% higher in women who went on 227 228 to develop breast cancer compared to those who did not ($p \le 0.05$, Tables 3 and 4).

229

230 3.4 Metabolome-Wide Association Study (MWAS) of T2 Environmental Chemicals

231 Prior studies have identified inflammatory lipid pathways (linoleate, arachidonate,

prostaglandin), lipid and energy metabolism pathways (fatty acids, TCA cycle), oxidative stress

pathways (methionine and cysteine), and nitrogen metabolism pathways (urea cycle, pyrimidine,

234 purine) as top metabolic pathway associations with environmental chemicals and breast cancer

235	(Hu et al. 2019; Li et al. 2020; Walker et al. 2019). To determine whether the features annotated
236	as environmental chemicals (Table 3) are associated with changes in metabolites and metabolic
237	pathways, we used data-driven integration and network analysis of the T3DB annotated features
238	and all 9042 extracted metabolic signals, with xMWAS (Uppal et al. 2018). As shown in Fig 2,
239	network analysis showed three metabolic communities, Community 1 (C1, orange), Community
240	2 (C2, blue) and Community 3 (C3, green). C1 was positively associated with m/z 315.1957
241	(F1, Fig 2, Table 3). We performed metabolic pathway enrichment analysis (Fig 3) on the 716
242	metabolic features associated with C1 using the mummichog 3 software (Li et al. 2013).
243	Associated pathways included linoleate, arachidonate and prostaglandins (Fig 3A), which are
244	closely related to inflammation and oxidative stress. Database searches showed that m/z
245	315.1957 matched multiple lipids (e.g., prostaglandins, resolvins), consistent with the strong
246	associations with related lipid species having activities in inflammation. The vitamin A pathway
247	was also associated with C1 (Fig 3A), and targeted mass spectrometry with MS/MS analysis
248	showed a likelihood that m/z 315.1957 was 4-hydroxyretinoic acid (F1, Supplemental Fig. S1).
249	
250	C1 extensively overlapped with Community 2 (C2, blue), which was positively associated with
251	m/z 334.2090 (F2, Fig 2, Table 3). In addition to pathway associations with prostaglandins,
252	linoleic acid and arachidonic acid, a subset of C2 included phospholipids, e.g., sphingosine,
253	phosphatidyl choline (PC), and triglyceride (blue, Fig 2), associated with glycerophospholipid
254	metabolism. Thus, this chemical defines a separate cluster of metabolites associated with breast
255	cancer than those in C1, but this feature remains unidentified because subsequent mass
256	spectrometry analysis failed to provide support for identification. Together, results from C1 and
257	C2 support prior findings that inflammatory lipid and other lipid pathways associated with DDT,

PCB and PBB are associated with breast cancer, but do not reveal any new suspect

259 environmental chemicals.

260

261 A third community, C3, had metabolomic associations (green) which were separated from C1 and C2 and positively associated with m/z features annotated as environmental chemicals, 262 including an insecticide (F3, nitromethylene-piperidine), a wood preservation and dye production 263 chemical (F4, 2,4-dinitrophenol), oxalate (F5), and F6, *m/z* 156.0666 and F7, *m/z* 345.0777 (Fig 264 265 2, Table 3). Of these, oxalate was previously confirmed, and supportive targeted mass 266 spectrometry data was obtained for 2-nitromethylene-piperidine and 2,4-dinitrophenol (F3 and 267 **F5, Supplemental Fig. S1**). The m/z feature 156.0666 (F6) was present at high concentrations in most samples and appeared likely to be an endogenous metabolite, N-acetylproline (F6, 268 269 **Supplemental Fig. S1**). No supportive mass spectrometry data could be obtained for the m/z. 270 feature 345.0777 (F7). The 56 metabolic features in C3 that were positively associated with 271 these annotated environmental chemicals were related to pathways for antioxidant methionine 272 (Met) and cysteine (Cys) regulation, urea cycle, amino acids (glycine, serine, alanine, threonine, 273 aspartate, asparagine, lysine), glycerophospholipids, and purine and pyrimidine nucleotide 274 metabolism (Fig 3C). Representative metabolites associated with these pathways of each 275 community are indicated next to each community (Fig 2) and included amino acids (glutamate, 276 serine, lysine, aspartate), a pyrimidine (orotidine), a purine (uric acid), and a coenzyme for mitochondrial electron transfer and the TCA cycle (dihydrolipoamide). Collectively, the results 277 278 for T2 serum of women who subsequently developed breast cancer show that two suspect 279 environmental chemicals, nitromethylene-piperidine and 2,4-dinitrophenol, along with oxalate, 280 are closely associated with metabolic perturbations related to amino acid and nucleotide

281	metabolism. Other communities included lipids functioning in inflammation, sphingolipids and
282	lipids, but no suspect environmental chemicals were identified for these communities.
283	
284	3.5 MWAS of T3 Environmental Chemicals and alterations in metabolic pathway
285	Following the same experimental approach shown above, we examined the relationship of
286	annotated matches of T3 suspect environmental chemicals (Table 4) and changes in metabolites
287	using xMWAS (Uppal et al. 2018). Two major metabolic communities were identified (Fig 4),
288	with the first community (labeled C4, orange) including metabolites associated exclusively with
289	m/z 271.1195 (F18) and second community (C5, blue) including metabolites associated with m/z
290	214.9728 (F19), <i>m/z</i> 217.0866 (F20) and <i>m/z</i> 215.0327 (F21) (Fig 4). Targeted mass
291	spectrometry analysis of m/z 271.1195 (F18) showed that this feature was likely ergosterol or
292	related derivative (F18, Supplemental Fig. S2). Pathway enrichment analysis of the 650
293	metabolic features of C4 showed associated pathways for arachidonate, leukotriene, linoleate,
294	vitamin A, prostaglandins, vitamin E and steroid hormones (Fig 5A). Most of these pathways
295	are closely related to inflammation and oxidative stress, as also found in T2 associations in C1
296	and C2 (Fig 3A, 3B). Targeted mass spectrometry analyses showed that m/z 214.9713 (F19) was
297	likely a bromine adduct of a benzoic acid metabolite (F19, Supplemental Fig. S2); m/z
298	217.0866 (F20) had an MS^2 spectrum with 83% match to benzo[a]carbazole (F20 ,
299	Supplemental Fig. S2); m/z 215.0327 (F21) was a high abundance signal from glucose (F21,
300	Supplemental Fig. S2). Pathway enrichment analysis of the 155 metabolic features in C5
301	showed associations for sialic acid, pentose phosphate, N-glycan degradation, galactose,
302	phosphatidylinositol, glycolysis and gluconeogenesis, butanoate, and glycosphingolipid
303	pathways (Fig 5B). Representative metabolites associated with these pathways are indicated next

304	to each community (Fig 4). Collectively, suspect environmental chemicals in Communities 4			
305	and 5 include a benzoate derivative and benzo[a]carbazole, and metabolic pathway associations			
306	suggesting that breast cancer effects could be mediated through inflammatory lipids, glucose-			
307	related metabolism and estrogenic signaling.			
308				
309	3.6 Comparisons of T2 and T3 suspect chemical-metabolic pathway associations			
310	In comparison of findings for T3 and T2, metabolic pathways for C4 in T3 showed considerable			
311	overlap with the pathways associated with C1 and C2 in T2. In contrast, the remaining			
312	community, C5, in T3 differed substantially from the remaining community, C3, in T2.			
313	Specifically, in T3, we identified a suspect benzoate and benzo[a]carbazole in breast cancer			
314	cases that were associated with pathways of carbohydrate metabolism functioning in			
315	extracellular matrix turnover and complex carbohydrate metabolism. In T2, we identified a			
316	suspect insecticide, 2-nitromethylpiperidine, a widely used commercial chemical, 2,4-			
317	dinitrophenol, and oxalic acid, in breast cancer cases that were associated with central pathways			
318	functioning in amino acid homeostasis, urea cycle, pyrimidine and purine metabolism, and			
319	defense against oxidative stress.			

321 4. Discussion

322 The present study applies a new exposome epidemiology approach to discover suspect 323 environmental chemicals that may be implicated in breast cancer development. New suspect 324 chemicals from this analysis include an insecticide, nitromethylene-piperidine; a common commercial chemical, 2,4-dinitrophenol; a heterocyclic amine with diverse commercial 325 326 applications, benzo[a]carbazole; a benzoate derivative which could be derived from natural products or environmental chemicals; and oxalate, an endogenous metabolite that is also used as 327 a cleaning agent. These chemicals were at higher abundance in serum of women decades before 328 329 breast cancer diagnosis. Importantly, the network analysis is data-dependent, raising the 330 possibility that individual chemicals could have a causal role in breast cancer or that breast cancer could occur through interaction of multiple chemicals in causal mechanisms. In the latter 331 case, individual variations in exposure could have important impact on risk. 332

333

New approaches to identify suspect carcinogens are critical because research over the last 50 334 335 years has not translated to a strategy for individual breast cancer prevention. The suspect chemical signal F18 (m/z 271.1195) in Community 4, was consistent with identification as 336 ergosterol, which is derived from yeast and precursor of vitamin D2. Pathway mapping of this 337 community showed overlap with inflammatory lipid pathways found in Communities 1 and 2, 338 and also included vitamin A metabolism, which is consistent with feature F1 in Community 1, 4-339 340 hydroxyretinoic acid, being a suspect chemical. Many diet-derived carotenoids can be converted 341 to isobaric species to 4-hydroxyretinoic acid, and these are not distinguished by the HRM methods used. Thus, future research will be needed to address the potential for diet-environment 342 343 interactions, such as implied by the overlap of estrogen-, vitamin D- and vitamin A-linked

metabolites. Pregnancy impacts initiation, progression, and susceptibility to breast cancer (Troisi *et al.* 2018), and therefore pregnancy provides an appropriate time frame for study. Later age at pregnancy is a long-established breast cancer risk factor (Albrektsen *et al.* 2005; MacMahon *et al.* 1970) which has become increasingly common and is still unexplained. Because first birth rates have increased 6-fold for women ages 35-39 from 1973-2006 (Martin *et al.* 2015), more detailed understanding of the respective contributions and interactions must be a priority to learn how to mitigate risk for this population group of higher risk women.

351

In T2, an additional chemical cluster containing an insecticide (nitromethylene-piperidine), a

cleaning agent (oxalate), a chemical used in wood preservation and dye production

354 (dinitrophenol), and two unidentified chemical features (F2, F7), were associated with multiple

amino acid pathways and nitrogen metabolism (urea cycle, pyrimidine, purine). The amino acid

356 pathways overlap with pathways previously found to vary with persistent organic pollutants,

357 *p*,*p*'-DDT (Hu *et al.* 2020) and PBBs (Walker *et al.* 2019). In a multigenerational study, *p*,*p*'-

358 DDT exposure in women before puberty was found to be associated with breast cancer in

mothers (Cohn *et al.* 2007) and in utero *o*',*p*'-DDT exposure was associated with breast cancer in

daughters (Cohn *et al.* 2015). Polybrominated biphenyls (PBB) are also persistent organic

361 pollutants that cause breast cancer (IARC 2015). Potential mechanistic connections between

dintrophenol, nitromethylene-piperidine, oxalate, and these POPs are not apparent, and

363 mechanisms by which POPs disrupt central amino acid and nitrogen metabolism pathways are

not known. In particular, amino acids are essential for growth and development, and disruption

365 of pyrimidine and purine metabolism can be expected to have long-term consequences on

metabolic programming which could contribute to cancer susceptibility. Thus, these findings
 warrant further investigation into underlying mechanisms related to breast cancer development.

369 In T3, the large metabolic community (C4, Fig 4) containing inflammatory lipids was linked to a sparse community (C5, Fig 4) containing glucose, benzo[a]carbazole and a suspect benzoate 370 371 derivative. Of potential importance in this network, the glucose signal was negatively associated 372 with metabolites connected to sialic acid, N-glycan and other pathways associated with 373 extracellular matrix and turnover of connective tissue. Benzoate is conjugated with glycine for 374 elimination, and the role of glycine in folate-dependent metabolism through the vitamin B_{6} -375 dependent hydroxymethyltransferase raises the possibility that benzoate derivatives could have unrecognized pathogenic effects. Similarly, the heterocyclic amine, benzo[a]carbazole, could be 376 377 bioactivated by Cyp enzymes to generate mutagenic species which have not been characterized. Future hypothesis-driven research will be needed to address these possibilities. 378

379

380 The exposome epidemiology approach used in the present study has important assumptions, i.e., that chemical exposures which increase cancer risk can occur decades before breast cancer 381 382 occurrence, that these exposures are detectable and at higher abundance in serum decades prior 383 to breast cancer detection, and that network analyses of HRM data are sufficient to detect these exposures and link them to biologic responses. With these assumptions, all HRM features from 384 385 archival blood serum of women collected decades before breast cancer diagnosis can be used in a 386 non-targeted manner to select ones that are increased (p<0.05) in association with breast cancer occurrence. This selection criterion is not suitable for biomarker development because of 387 388 multiple testing; however, this cutoff is suitable for discovery of potential chemical risk factors

because any of the features at this cutoff could be correct. The selected HRM features are then used with a toxic exposome database, T3DB, to obtain accurate mass matches to known toxic chemicals, and these are subjected to non-targeted network and pathway enrichment analyses to identify environmental chemical-metabolic network associations linked to breast cancer outcome.

394

Exposome epidemiology will benefit from populations of tens or hundreds of thousands of 395 individuals by enabling detection of exposures impacting small numbers of women and/or 396 397 having only small contributions individually to breast cancer risk. The present study with only hundreds rather than thousands of individuals has limited capability to detect carcinogens with 398 small effect size. Additionally, selection of HRM features for statistical selection in the current 399 400 study required that features be present in 80% of the samples. Environmental chemicals and personal use products such as hair dyes cannot be expected to be present in 80% of the women 401 and unlikely to be detectable. Application of untargeted gas chromatography-high-resolution 402 403 mass spectrometry, which provides capabilities to measure other hydrophobic and volatile environmental chemicals (Hu et al. 2021), can be used to enhance coverage of environmental 404 405 chemicals. Thus, future studies will benefit from larger population sizes, inclusion of complementary chemical analyses, and use of statistical methods which can accommodate sparse 406 environmental chemical detection. 407

408

409 **5. Conclusion**

Recent technological and statistical advances in high-resolution metabolomics (HRM) provide
capabilities for omics scale biomonitoring of chemicals derived from the environment along with

412	endogenous metabolism and chemicals from the diet, intestinal microbiome, dietary supplements,
413	pharmaceuticals, and personal use products. Because the metabolome is a functional readout of
414	the interactions of a person's genes with exposures, HRM of biologic samples provides one of
415	the most accessible ways to connect environmental exposures with biologic status to anticipate
416	breast cancer. As shown in the present study, these can be used with network and pathway
417	analysis to identify suspect environmental chemicals and functional communities linked to breast
418	cancer outcome. Such network approaches can be broadly applied to discover how life-long
419	exposures impact personal cancer risks. For breast cancer, we believe that this approach will
420	yield critically needed protocols to enhance protection or mediate pregnancy-associated risk.
421	
422	Funding: This study was supported by Department of Defense Grant W81XWH2010103, and
423	National Institute of Environmental Health and Science grant R21 ES031824, R01 ES031980
424	and P30 ES019776.

426 **References**

428	Albrektsen, G.; Heuch, I.; Hansen, S.; Kvale, G. Breast cancer risk by age at birth, time since
429	birth and time intervals between births: exploring interaction effects. British Journal of
430	Cancer 2005;92:167-175
431	Cohn, B.A.; Cirillo, P.M.; Hopper, B.R.; Siiteri, P.K. Third Trimester Estrogens and Maternal
432	Breast Cancer: Prospective Evidence. J Clin Endocrinol Metab 2017;102:3739-3748
433	Cohn, B.A.; La Merrill, M.; Krigbaum, N.Y.; Yeh, G.; Park, J.S.; Zimmermann, L.; Cirillo, P.M.
434	DDT Exposure in Utero and Breast Cancer. J Clin Endocrinol Metab 2015;100:2865-
435	2872
436	Cohn, B.A.; Wolff, M.S.; Cirillo, P.M.; Sholtz, R.I. DDT and breast cancer in young women:
437	new data on the significance of age at exposure. Environ Health Perspect 2007;115:1406-
438	1414
439	Go, Y.M.; Kim, C.W.; Walker, D.I.; Kang, D.W.; Kumar, S.; Orr, M.; Uppal, K.; Quyyumi, A.A.;
440	Jo, H.; Jones, D.P. Disturbed flow induces systemic changes in metabolites in mouse
441	plasma: a metabolomics study using ApoE(-)/(-) mice with partial carotid ligation. Am J
442	Physiol Regul Integr Comp Physiol 2015;308:R62-72
443	Hu, X.; Li, S.; Cirillo, P.; Krigbaum, N.; Tran, V.; Ishikawa, T.; La Merrill, M.A.; Jones, D.P.;
444	Cohn, B. Metabolome Wide Association Study of serum DDT and DDE in Pregnancy
445	and Early Postpartum. Reprod Toxicol 2020;92:129-137
446	Hu, X.; Li, S.; Cirillo, P.M.; Krigbaum, N.Y.; Tran, V.; Jones, D.P.; Cohn, B.A. Metabolome
447	Wide Association Study of Serum Poly and Perfluoroalkyl Substances (PFASs) in
448	Pregnancy and Early Postpartum. Reprod Toxicol 2019;87:70-78

449	Hu, X.; Walker, D.I.; Liang, Y.; Smith, M.R.; Orr, M.L.; Juran, B.D.; Ma, C.; Uppal, K.; Koval,			
450	M.; Martin, G.S.; Neujahr, D.C.; Marsit, C.J.; Go, Y.M.; Pennell, K.D.; Miller, G.W.;			
451	Lazaridis, K.N.; Jones, D.P. A scalable workflow to characterize the human exposome.			
452	Nat Commun 2021;12:5575			
453	IARC. Polychlorinated Biphenyls and Polybrominated Biphenyls ed^eds; 2015			
454	Jarrell, Z.R.; Smith, M.R.; He, X.; Orr, M.; Jones, D.P.; Go, Y.M. Firsthand and Secondhand			
455	Exposure Levels of Maltol-Flavored Electronic Nicotine Delivery System Vapors Disrupt			
456	Amino Acid Metabolism. Toxicol Sci 2021;182:70-81			
457	Jarrell, Z.R.; Smith, M.R.; Hu, X.; Orr, M.; Liu, K.H.; Quyyumi, A.A.; Jones, D.P.; Go, Y.M.			
458	Plasma acylcarnitine levels increase with healthy aging. Aging (Albany NY)			
459	2020;12:13555-13570			
460	Johnson, C.H.; Athersuch, T.J.; Collman, G.W.; Dhungana, S.; Grant, D.F.; Jones, D.P.; Patel,			
461	C.J.; Vasiliou, V. Yale school of public health symposium on lifetime exposures and			
462	human health: the exposome; summary and future reflections. Human genomics			
463	2017;11:32			
464	Jones, D.P.; Cohn, B.A. A vision for exposome epidemiology: The pregnancy exposome in			
465	relation to breast cancer in the Child Health and Development Studies. Reprod Toxicol			
466	2020;92:4-10			
467	Jones, D.P.; Park, Y.; Ziegler, T.R. Nutritional metabolomics: progress in addressing complexity			
468	in diet and health. Annu Rev Nutr 2012;32:183-202			
469	Jones, D.P.; Walker, D.I.; Uppal, K.; Rohrbeck, P.; Mallon, C.T.; Go, Y.M. Metabolic Pathways			
470	and Networks Associated With Tobacco Use in Military Personnel. Journal of			
471	occupational and environmental medicine 2016;58:S111-116			

472	Li, S.; Cirillo, P.; Hu, X.; Tran, V.; Krigbaum, N.; Yu, S.; Jones, D.P.; Cohn, B. Understanding
473	mixed environmental exposures using metabolomics via a hierarchical community
474	network model in a cohort of California women in 1960's. Reprod Toxicol 2020;92:57-65
475	Li, S.; Park, Y.; Duraisingham, S.; Strobel, F.H.; Khan, N.; Soltow, Q.A.; Jones, D.P.; Pulendran,
476	B. Predicting network activity from high throughput metabolomics. PLoS Comput Biol
477	2013;9:e1003123
478	Liang, D.; Moutinho, J.L.; Golan, R.; Yu, T.; Ladva, C.N.; Niedzwiecki, M.; Walker, D.I.;
479	Sarnat, S.E.; Chang, H.H.; Greenwald, R.; Jones, D.P.; Russell, A.G.; Sarnat, J.A. Use of
480	high-resolution metabolomics for the identification of metabolic signals associated with
481	traffic-related air pollution. Environ Int 2018;120:145-154
482	Lim, E.; Pon, A.; Djoumbou, Y.; Knox, C.; Shrivastava, S.; Guo, A.C.; Neveu, V.; Wishart, D.S.
483	T3DB: a comprehensively annotated database of common toxins and their targets.
484	Nucleic Acids Res 2010;38:D781-786
485	MacMahon, B.; Cole, P.; Lin, T.M.; Lowe, C.R.; Mirra, A.P.; Ravnihar, B.; Salber, E.J.;
486	Valaoras, V.G.; Yuasa, S. Age at first birth and breast cancer risk. Bull World Health
487	Organ 1970;43:209-221
488	Martin, J.; Hamilton, B.; Osterman, M.; Curtin, S.; Matthews, T. Births: final data for 2013.
489	National vital statistics reports: from the Centers for Disease Control and Prevention,
490	National Center for Health Statistics, National Vital Statistics System 2015;64:1
491	Niedzwiecki, M.M.; Walker, D.I.; Vermeulen, R.; Chadeau-Hyam, M.; Jones, D.P.; Miller, G.W.
492	The Exposome: Molecules to Populations. Annu Rev Pharmacol Toxicol 2019;59:107-
493	127

494	Perkins, C.; Wright, W.; Schlag, R. Cancer Incidence and Mortality in California, 1988-1994,		
495	CA: California Department of Health Servicies, Cancer Surveilance Section.		
496	Ritz, B.; Yan, Q.; He, D.; Wu, J.; Walker, D.I.; Uppal, K.; Jones, D.P.; Heck, J.E. Child serum		
497	metabolome and traffic-related air pollution exposure in pregnancy. Environ Res		
498	2022;203:111907		
499	Scalbert, A.; Andres-Lacueva, C.; Arita, M.; Kroon, P.; Manach, C.; Urpi-Sarda, M.; Wishart, D.		
500	Databases on food phytochemicals and their health-promoting effects. J Agric Food		
501	Chem 2011;59:4331-4348		
502	Schymanski, E.L.; Jeon, J.; Gulde, R.; Fenner, K.; Ruff, M.; Singer, H.P.; Hollender, J.		
503	Identifying small molecules via high resolution mass spectrometry: communicating		
504	confidence. Environ Sci Technol 2014;48:2097-2098		
505	Troisi, R.; Bjørge, T.; Gissler, M.; Grotmol, T.; Kitahara, C.M.; Myrtveit Saether, S.; Ording,		
506	A.G.; Sköld, C.; Sørensen, H.T.; Trabert, B. The role of pregnancy, perinatal factors and		
507	hormones in maternal cancer risk: a review of the evidence. J Intern Med 2018;283:430-		
508	445		
509	Uppal, K.; Ma, C.; Go, Y.M.; Jones, D.P.; Wren, J. xMWAS: a data-driven integration and		
510	differential network analysis tool. Bioinformatics 2018;34:701-702		
511	Uppal, K.; Walker, D.I.; Jones, D.P. xMSannotator: An R Package for Network-Based		
512	Annotation of High-Resolution Metabolomics Data. Anal Chem 2017;89:1063-1067		
513	van den Berg, B.J.; Christianson, R.E.; Oechsli, F.W. The California Child Health and		
514	Development Studies of the School of Public Health, University of California at Berkeley.		
515	Paediatr Perinat Epidemiol 1988;2:265-282		

- 516 Walker, D.I.; Marder, M.E.; Yano, Y.; Terrell, M.; Liang, Y.; Barr, D.B.; Miller, G.W.; Jones,
- 517 D.P.; Marcus, M.; Pennell, K.D. Multigenerational metabolic profiling in the Michigan
- 518 PBB registry. Environ Res 2019;172:182-193
- 519 Wilkinson, M.D.; Dumontier, M.; Aalbersberg, I.J.; Appleton, G.; Axton, M.; Baak, A.;
- 520 Blomberg, N.; Boiten, J.W.; da Silva Santos, L.B.; Bourne, P.E.; Bouwman, J.; Brookes,
- 521 A.J.; Clark, T.; Crosas, M.; Dillo, I.; Dumon, O.; Edmunds, S.; Evelo, C.T.; Finkers, R.;
- 522 Gonzalez-Beltran, A.; Gray, A.J.; Groth, P.; Goble, C.; Grethe, J.S.; Heringa, J.; t Hoen,
- 523 P.A.; Hooft, R.; Kuhn, T.; Kok, R.; Kok, J.; Lusher, S.J.; Martone, M.E.; Mons, A.;
- 524 Packer, A.L.; Persson, B.; Rocca-Serra, P.; Roos, M.; van Schaik, R.; Sansone, S.A.;
- 525 Schultes, E.; Sengstag, T.; Slater, T.; Strawn, G.; Swertz, M.A.; Thompson, M.; van der
- 526 Lei, J.; van Mulligen, E.; Velterop, J.; Waagmeester, A.; Wittenburg, P.; Wolstencroft, K.;
- 527 Zhao, J.; Mons, B. The FAIR Guiding Principles for scientific data management and
- 528 stewardship. Sci Data 2016;3:160018
- 529 Wishart, D.; Arndt, D.; Pon, A.; Sajed, T.; Guo, A.C.; Djoumbou, Y.; Knox, C.; Wilson, M.;
- Liang, Y.; Grant, J.; Liu, Y.; Goldansaz, S.A.; Rappaport, S.M. T3DB: the toxic

exposome database. Nucleic Acids Res 2015;43:D928-934

Wishart, D.S. Identifying putative drug targets and potential drug leads: starting points for virtual
 screening and docking. Methods Mol Biol 2015;1215:425-444

- 534 Wishart, D.S.; Tzur, D.; Knox, C.; Eisner, R.; Guo, A.C.; Young, N.; Cheng, D.; Jewell, K.;
- 535 Arndt, D.; Sawhney, S.; Fung, C.; Nikolai, L.; Lewis, M.; Coutouly, M.A.; Forsythe, I.;
- 536 Tang, P.; Shrivastava, S.; Jeroncic, K.; Stothard, P.; Amegbey, G.; Block, D.; Hau, D.D.;
- 537 Wagner, J.; Miniaci, J.; Clements, M.; Gebremedhin, M.; Guo, N.; Zhang, Y.; Duggan,
- 538 G.E.; Macinnis, G.D.; Weljie, A.M.; Dowlatabadi, R.; Bamforth, F.; Clive, D.; Greiner,

539 R.; Li, L.; Marrie, T.; Sykes, B.D.; Vogel, H.J.; Querengesser, L. HMDB: the Human

540 Metabolome Database. Nucleic Acids Res 2007;35:D521-526

541 Figure Legends

542

Figure 1. Exposome Epidemiology Workflow. The steps used in the current analysis are 543 544 summarized in general form. In the first step, the study population and sample types can be selected for diverse purposes. In the second step, liquid chromatography, gas chromatography or 545 546 other separation methods can be used with high-resolution mass spectrometry to generate tens of 547 thousands of mass spectral features. For this purpose, multiple data extraction tools are 548 available, and extraction parameters and filtration criteria can be selected to increase stringency 549 or leniency in feature retention. For the third step, directionality of change is selected for features expected to have a causal or protective activity. For the fourth step, selected features are 550 annotated using a relevant database. In the fifth step, selected and annotated features are used 551 552 with network analysis to identify associated communities of mass spectral features. The sixth 553 step applies pathway enrichment analysis to the associated communities of mass spectral features 554 to characterize the associated biologic response. Finally, targeted mass spectral analysis of 555 relevant mass spectral features provides prioritization for subsequent hypothesis-driven research 556 to verify environmental chemical associations and underlying causal mechanisms.

557

Figure 2. Metabolome-Wide Association Study (MWAS) of T3DB-annotated chemicals higher in second trimester (T2) serum. Association of seventeen T3DB-annotated features (Table 3) that are higher in breast cancer than non-cases with the metabolome (9,042 metabolic features) from T2 serum (n=384 for non-cases, n=182 for breast cancer) are examined using xMWAS. The outcome of xMWAS analysis is visualized with two separate networks at $|\mathbf{r}| \ge 0.3$. The networks include three communities (C1, C2, C3) and show central seven chemicals (F1-F7) with tight

564	connections [C1 (orange). C2 (blue), C3 (green)]. Representative metabolites of pathways
565	associated with community are shown next to each community. DHET: dihydroxyeicosatrienoic
566	acid, EETA: epoxyeicosatrienoic acid, TG: triglyceride, PC: phosphatidylcholine.
567	
568	Figure 3. Metabolic pathway associated with second trimester (T2) chemicals. Pathway
569	enrichment analysis with metabolites of three network communities in Fig. 2 was conducted
570	using mummichog. A) A total of seven pathways were found altered with m/z 315.1957 (F1) in
571	C1, B) Eight pathways were altered with m/z 334.2090 (F2) in C2, and C) Seven pathways were
572	altered with environmental chemicals and drug metabolites (F3-F7) ($p < 0.05$). The ratio of
573	selected metabolites mapped to the listed pathway over the number of total pathway metabolites
574	detected is provided to the right of each bar.
575	
576	Figure 4. Metabolome-Wide Association Study (MWAS) of T3DB-annotated chemicals higher
577	in third trimester (T3) serum. Association of seven T3DB-annotated chemicals (Table 4) that are
578	higher in breast cancer than non-cases with the metabolome (9,042 metabolic features) from T3
579	serum (n=351 for non-cases, n=172 for breast cancer) are examined using xMWAS. The network
580	is visualized at $ r \ge 0.3$ and includes two communities (C4 and C5) showing central four
581	chemicals with tight connections [C4 (orange)] than C5 (blue)]. Representative metabolites of
582	pathways associated with community are shown next to each community.
583	
584	Figure 5. Metabolic pathway associated with T3 chemicals. Pathway enrichment analysis with
585	metabolites of two network communities in Fig. 4 was conducted using mummichog. A) Seven
586	pathways were found altered with F18 chemical in C1 and B) eight pathways were altered with

- chemicals (F19-F21) in C2 (p < 0.05). The ratio of selected metabolites mapped to the listed
- 588 pathway over the number of total pathway metabolites detected is provided to the right of each

589 bar.

590 **Table 1.** Characteristics of Study Population

	Non-Ca (N=41	ises 3)	Cases (N	=201)
Characteristic	Median	(IQR)	Median	(IQR)
Year of mother's birth	1936	(9)	1931	(11)
Year of blood draw	1962	(2)	1962	(2)
Gestational day of T2 blood draw	160	(33)	161	(29)
Gestational day of T3 blood draw	250	(17)	249	(16)
BMI at first prenatal visit $(kg/m^2)^a$	22.1	(4.3)	22.6	(4.2)
Characteristic	Percent		Percent	
Race				
non-Hispanic Caucasian	70		69	
African American	20		19	
Hispanic	2		1	
Asian	6		7	
Mixed	2		3	

Table 2. HRM profiling of T2 and T3 serum samples comparing breast case and non-case

592 groups ($P \le 0.05$). BC, breast cancer.

	T2 (182 BC, 384 non-	T3 (172 BC, 351 non-
	cases)	cases)
Total number of metabolic features	9042	9042
Eastures differing at n <0.05	521	557
reatures differing at. $p < 0.05$	521	557
Differing features with BC/non-cases	188	151
ratio > 1.0		

Table 3. T3DB-annotated m/z features higher in T2 serum of women who subsequently

developed breast cancer (BC) compared with non-cases ($P \le 0.05$). Targeted mass spectrometry

analysis was performed to aid in identification of features F1 to F7 which were found to occur in

central communities of Fig 2, indicated by asterisk (*). T3DB annotations are provided for others

597 (F8-F17).

Feature	Name	m/z.	RT (sec)	% Higher in BC	Category
F1*	4-Hydroxyretinoic acid	315.1957	177	20	Vitamin A
					metabolite
F2*	Unidentified	334.2090	125	20	Unidentified
F3*	2-Nitromethylene-	141.0670	278	10	Insecticide
	piperidine				
F4*	2,4-Dinitrophenol	183.0046	283	10	Multiple
					commercial
					uses
F5*	Oxalic Acid	88.9883	129	10	Cleaning agent
F6*		156.0666	283	10	Endogenous
	N-acetyl-proline				metabolite
F7*	Unidentified	345.0777	51	20	Unidentified
		225.0712	139	30	Anti-
F8	Flurbiprofen				inflammatory
					drug

F9	Quaternium-52	610.4093	195	20	Quaternary ammonium salt
F10	Ethyl cyanoacrylate	124.0404	14	10	Cyanoacrylate glue component
F11	2-Chloro-4,5-xylyl N-	228.0427	284	10	Cholinesterase
	hydroxy-N-				inhibitor
	methylcarbamate				
F12	Psoralen, Angelicin	167.0135	20	20	Skin nodule
					treatment,
F13	Hexazinone	273.1344	32	10	Herbicide
F14	MHP (Methyl hydrogen	179.0350	138	10	Organic
	phthalate)				compound
F15	2-Hydroxyphenyl	166.0508	212	10	Pesticide
	methylcarbamate				
F16	Levodona	178.0510	23	20	Dopamine
					precursor drug
F17	Phenylmercuric acetate	337.0157	22	20	Preservative

Table 4. T3DB-annotated m/z features higher in T3 serum of women who subsequently developed breast cancer (BC) compared with those in the non-case women ($P \le 0.05$). Targeted mass spectrometry analysis was performed to aid in identification of features F18-F21 which were found to occur in central communities of Fig 4, indicated by asterisk (*). T3DB annotation is provided for others (F22-F24).

Feature	Name	m/z	RT (sec)	% Higher in BC	Category
F18*	Ergosterol	271.1195	25	10	Vitamin D2 precursor
F19*	Benzoate derivative	214.9728	22.8	10	Food preservative
F20*	Benzo[a]carbazole	217.0866	21	10	Heterocyclic amine
F21*	Glucose	215.0327	23	10	Endogenous metabolite
F22	Trimethadione	142.0509	277	10	Anticonvulsant
F23	Heptabromobiphenyl	734.4246	195	20	Aromatic compound
F24	Chlorpromazine	317.0876	135	10	Antipsychotics

603 **Fig 1.**









